12th Roche Diabetes Care Network Meeting: April 11-13, 2019, Copenhagen, Denmark

被引：0
作者：
Parkin, Christopher G. [1 ]
Zepezauer, Christine [2 ]
Hinzmann, Rolf [2 ]
机构：
[1] CGParkin Commun Inc, 2352 Martinique Ave, Henderson, NV 89044 USA
[2] Roche Diabet Care GmbH, Mannheim, Germany
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2020年 / 22卷 / 02期
关键词：
Continuous Glucose Monitoring (CGM); Self-Monitoring of Blood Glucose (SMBG); m-Health; Behavior; Closed loop; CONTINUOUS GLUCOSE SENSOR; PROSPECTIVE MULTICENTER EVALUATION; LIFE-STYLE INTERVENTIONS; MEALTIME INSULIN ASPART; BASAL-BOLUS TREATMENT; CARDIOVASCULAR-DISEASE; CLINICAL INERTIA; TYPE-1; RISK; MANAGEMENT;
D O I：
10.1089/dia.2019.0392
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A panel of international experts in the field of diabetes and diabetes technology met in Copenhagen, Denmark, for the 12th Roche Diabetes Care Network Meeting. The goal of these meetings is to share current knowledge, facilitate new collaborations, and encourage further research projects that can improve the lives of people with diabetes. Specific areas of interest included use of telemedicine and mobile health technologies, behavior change, patient-centered care, and multifactorial approaches to addressing all metabolic abnormalities associated with diabetes. The 2019 meeting covered a comprehensive scientific program and four keynote lectures.
引用
收藏
页码：142 / 167
页数：26
相关论文
共 67 条
  • [1] First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes
    Aronson, Ronnie
    Abitbol, Alexander
    Tweden, Katherine S.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (07) : 1689 - 1694
  • [2] Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
    Battelino, Tadej
    Danne, Thomas
    Bergenstal, Richard M.
    Amiel, Stephanie A.
    Beck, Roy
    Biester, Torben
    Bosi, Emanuele
    Buckingham, Bruce A.
    Cefalu, William T.
    Close, Kelly L.
    Cobelli, Claudio
    Dassau, Eyal
    DeVries, J. Hans
    Donaghue, Kim C.
    Dovc, Klemen
    Doyle, Francis J.
    Garg, Satish
    Grunberger, George
    Heller, Simon
    Heinemann, Lutz
    Hirsch, Irl B.
    Hovorka, Roman
    Jia, Weiping
    Kordonouri, Olga
    Kovatchev, Boris
    Kowalski, Aaron
    Laffel, Lori
    Levine, Brian
    Mayorov, Alexander
    Mathieu, Chantal
    Murphy, Helen R.
    Nimri, Revital
    Norgaard, Kirsten
    Parkin, Christopher G.
    Renard, Eric
    Rodbard, David
    Saboo, Banshi
    Schatz, Desmond
    Stoner, Keaton
    Urakami, Tatsuiko
    Weinzimer, Stuart A.
    Phillip, Moshe
    [J]. DIABETES CARE, 2019, 42 (08) : 1593 - 1603
  • [3] A comparison of observational studies and randomized, controlled trials.
    Benson, K
    Hartz, AJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) : 1878 - 1886
  • [4] Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes
    Bergenstal, Richard M.
    Garg, Satish
    Weinzimer, Stuart A.
    Buckingham, Bruce A.
    Bode, Bruce W.
    Tamborlane, William V.
    Kaufman, Francine R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (13): : 1407 - 1408
  • [5] Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
    Billings, Liana K.
    Doshi, Ankur
    Gouet, Didier
    Oviedo, Alejandra
    Rodbard, Helena W.
    Tentolouris, Nikolaos
    Gron, Randi
    Halladin, Natalie
    Jodar, Esteban
    [J]. DIABETES CARE, 2018, 41 (05) : 1009 - 1016
  • [6] Intestinal permeability - a new target for disease prevention and therapy
    Bischoff, Stephan C.
    Barbara, Giovanni
    Buurman, Wim
    Ockhuizen, Theo
    Schulzke, Joerg-Dieter
    Serino, Matteo
    Tilg, Herbert
    Watson, Alastair
    Wells, Jerry M.
    [J]. BMC GASTROENTEROLOGY, 2014, 14
  • [7] Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial
    Bode, B. W.
    Buse, J. B.
    Fisher, M.
    Garg, S. K.
    Marre, M.
    Merker, L.
    Renard, E.
    Russell-Jones, D. L.
    Hansen, C. T.
    Rana, A.
    Heller, S. R.
    [J]. DIABETIC MEDICINE, 2013, 30 (11) : 1293 - 1297
  • [8] BUSE JB, 2018, DIABETES S1, V67
  • [9] Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
    Carls, Ginger
    Huynh, Johnny
    Tuttle, Edward
    Yee, John
    Edelman, Steven V.
    [J]. DIABETES THERAPY, 2017, 8 (04) : 863 - 873
  • [10] Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes
    Carls, Ginger S.
    Tuttle, Edward
    Tan, Ruo-Ding
    Huynh, Johnny
    Yee, John
    Edelman, Steven V.
    Polonsky, William H.
    [J]. DIABETES CARE, 2017, 40 (11) : 1469 - 1478
1234567